GlaxoSmithKline Pharmaceuticals Ltd. - Research Center
500660 GLAXO Group (A) BSE data
Results
Statement
More
| Mar ' 24 |
Mar ' 23 |
Mar ' 22 |
Mar ' 21 |
Mar ' 20 |
Equity share capital
| 169.41 |
169.41 |
169.41 |
169.41 |
169.41 |
Share application money
Preference share capital
Reserves & surplus
| 1,623.69 |
1,585.27 |
2,508.21 |
1,327.71 |
1,670.63 |
Secured loans
Unsecured loans
Total
| 1,784.09 |
1,753.00 |
2,677.62 |
1,497.14 |
1,840.06 |
Gross block
| 604.38 |
585.48 |
553.28 |
571.90 |
1,408.98 |
Less : revaluation reserve
Less : accumulated depreciation
| 283.13 |
255.54 |
222.66 |
185.01 |
650.92 |
Net block
| 321.25 |
329.94 |
330.63 |
386.89 |
758.06 |
Capital work-in-progress
| 13.93 |
20.31 |
30.50 |
13.21 |
120.12 |
Investments
| 837.72 |
542.78 |
390.09 |
24.49 |
24.49 |
Current assets, loans & advances
| 2,374.90 |
2,434.67 |
3,871.38 |
2,672.48 |
2,228.85 |
Less : current liabilities & provisions
| 1,763.71 |
1,574.70 |
1,944.98 |
1,599.94 |
1,291.46 |
Total net current assets
| 611.19 |
859.97 |
1,926.40 |
1,072.54 |
937.39 |
Miscellaneous expenses not written
Total
| 1,784.09 |
1,753.00 |
2,677.62 |
1,497.14 |
1,840.06 |
Book value of unquoted investments
| 24.49 |
24.49 |
24.49 |
24.49 |
24.49 |
Market value of quoted investments
Contingent liabilities
| 383.96 |
358.51 |
365.29 |
493.24 |
483.04 |
Number of equity sharesoutstanding (Lacs)
| 1694.06 |
1694.06 |
1694.06 |
1694.06 |
1694.06 |